Research ExplorerPublicationsAlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report f...

AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation

Standard

AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. / Halaburda, Kazimierz; Labopin, Myriam; Houhou, Mohamed; Niederwieser, Dietger; Finke, Jürgen; Volin, Liisa; Maertens, Johan; Cornelissen, Jan J; Milpied, Noel; Stuhler, Gernot; Kröger, Nicolaus; Esteve, Jordi; Mohty, Mohamad; Nagler, Arnon.

In: BONE MARROW TRANSPL, Vol. 53, No. 6, 06.2018, p. 683-691.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Halaburda, K, Labopin, M, Houhou, M, Niederwieser, D, Finke, J, Volin, L, Maertens, J, Cornelissen, JJ, Milpied, N, Stuhler, G, Kröger, N, Esteve, J, Mohty, M & Nagler, A 2018, 'AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation', BONE MARROW TRANSPL, vol. 53, no. 6, pp. 683-691. https://doi.org/10.1038/s41409-018-0165-x

APA

Halaburda, K., Labopin, M., Houhou, M., Niederwieser, D., Finke, J., Volin, L., Maertens, J., Cornelissen, J. J., Milpied, N., Stuhler, G., Kröger, N., Esteve, J., Mohty, M., & Nagler, A. (2018). AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. BONE MARROW TRANSPL, 53(6), 683-691. https://doi.org/10.1038/s41409-018-0165-x

Vancouver

Halaburda K, Labopin M, Houhou M, Niederwieser D, Finke J, Volin L et al. AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. BONE MARROW TRANSPL. 2018 Jun;53(6):683-691. https://doi.org/10.1038/s41409-018-0165-x

Bibtex

@article{3ae8ea66cb79471098a62905c1d3a10f,
title = "AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation",
abstract = "Acute myeloid leukemia with inv(3)(q21;q26.2)/t(3;3)(q21;q26.2) (3q26 AML) is a rare disease with poor prognosis and median survival of <1 year. To evaluate allogeneic stem cell transplantation (alloHSCT) in the treatment of 3q26 AML, we studied 98 patients reported to the European Society for Blood and Marrow Transplantation between 1995 and 2013. Majority of patients were transplanted using peripheral blood, from unrelated donors and after myeloablative conditioning. Fifty-three patients were transplanted with active disease and 45 in complete remission. After a median follow-up of 47 months, 2 year leukemia-free survival (LFS), overall survival (OS), relapse incidence (RI), non-relapse mortality (NRM), and graft-versus-host disease-free, relapse-free survival (GRFS) probabilities were 20%, 26%, 64%, 16%, and 14%, respectively. Two-year LFS and OS probabilities for patients transplanted in CR vs. those transplanted in active disease were 23.8 vs. 17% (p = NS) and 34.9 vs. 18.9% (p = NS), respectively. In multivariate analysis CR was the only factor associated with a trend for better LFS (p = 0.05, HR 0.64) and OS (p = 0.06, HR 0.65). CR also significantly influenced GRFS (p = 0.01; HR 0.55) and NRM (p = 0.02; HR 0.27). The results suggest that a proportion of patients might benefit from the procedure, especially if performed in CR.",
keywords = "Journal Article",
author = "Kazimierz Halaburda and Myriam Labopin and Mohamed Houhou and Dietger Niederwieser and J{\"u}rgen Finke and Liisa Volin and Johan Maertens and Cornelissen, {Jan J} and Noel Milpied and Gernot Stuhler and Nicolaus Kr{\"o}ger and Jordi Esteve and Mohamad Mohty and Arnon Nagler",
year = "2018",
month = jun,
doi = "10.1038/s41409-018-0165-x",
language = "English",
volume = "53",
pages = "683--691",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "6",

}

RIS

TY - JOUR

T1 - AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation

AU - Halaburda, Kazimierz

AU - Labopin, Myriam

AU - Houhou, Mohamed

AU - Niederwieser, Dietger

AU - Finke, Jürgen

AU - Volin, Liisa

AU - Maertens, Johan

AU - Cornelissen, Jan J

AU - Milpied, Noel

AU - Stuhler, Gernot

AU - Kröger, Nicolaus

AU - Esteve, Jordi

AU - Mohty, Mohamad

AU - Nagler, Arnon

PY - 2018/6

Y1 - 2018/6

N2 - Acute myeloid leukemia with inv(3)(q21;q26.2)/t(3;3)(q21;q26.2) (3q26 AML) is a rare disease with poor prognosis and median survival of <1 year. To evaluate allogeneic stem cell transplantation (alloHSCT) in the treatment of 3q26 AML, we studied 98 patients reported to the European Society for Blood and Marrow Transplantation between 1995 and 2013. Majority of patients were transplanted using peripheral blood, from unrelated donors and after myeloablative conditioning. Fifty-three patients were transplanted with active disease and 45 in complete remission. After a median follow-up of 47 months, 2 year leukemia-free survival (LFS), overall survival (OS), relapse incidence (RI), non-relapse mortality (NRM), and graft-versus-host disease-free, relapse-free survival (GRFS) probabilities were 20%, 26%, 64%, 16%, and 14%, respectively. Two-year LFS and OS probabilities for patients transplanted in CR vs. those transplanted in active disease were 23.8 vs. 17% (p = NS) and 34.9 vs. 18.9% (p = NS), respectively. In multivariate analysis CR was the only factor associated with a trend for better LFS (p = 0.05, HR 0.64) and OS (p = 0.06, HR 0.65). CR also significantly influenced GRFS (p = 0.01; HR 0.55) and NRM (p = 0.02; HR 0.27). The results suggest that a proportion of patients might benefit from the procedure, especially if performed in CR.

AB - Acute myeloid leukemia with inv(3)(q21;q26.2)/t(3;3)(q21;q26.2) (3q26 AML) is a rare disease with poor prognosis and median survival of <1 year. To evaluate allogeneic stem cell transplantation (alloHSCT) in the treatment of 3q26 AML, we studied 98 patients reported to the European Society for Blood and Marrow Transplantation between 1995 and 2013. Majority of patients were transplanted using peripheral blood, from unrelated donors and after myeloablative conditioning. Fifty-three patients were transplanted with active disease and 45 in complete remission. After a median follow-up of 47 months, 2 year leukemia-free survival (LFS), overall survival (OS), relapse incidence (RI), non-relapse mortality (NRM), and graft-versus-host disease-free, relapse-free survival (GRFS) probabilities were 20%, 26%, 64%, 16%, and 14%, respectively. Two-year LFS and OS probabilities for patients transplanted in CR vs. those transplanted in active disease were 23.8 vs. 17% (p = NS) and 34.9 vs. 18.9% (p = NS), respectively. In multivariate analysis CR was the only factor associated with a trend for better LFS (p = 0.05, HR 0.64) and OS (p = 0.06, HR 0.65). CR also significantly influenced GRFS (p = 0.01; HR 0.55) and NRM (p = 0.02; HR 0.27). The results suggest that a proportion of patients might benefit from the procedure, especially if performed in CR.

KW - Journal Article

U2 - 10.1038/s41409-018-0165-x

DO - 10.1038/s41409-018-0165-x

M3 - SCORING: Journal article

C2 - 29670208

VL - 53

SP - 683

EP - 691

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 6

ER -